调胃、强肾扶正液联合吉非替尼分子靶向治疗非小细胞肺癌临床效果及安全性研究  

The Clinical Efficacy and Safety Study of Non-small-cell Lung Cancer were Targeted for the Treatment of Non-small-cell Lung Cancer in the Patients with Gastric Control and Renal Centronine

作　　者：孙佩佩 张颖颖 孙向红 SUN Peipei;ZHANG Yingying;SUN Xianghong(Binzhou Traditional Chinese Medicine Hospital,Binzhou,256600)

机构地区：[1]山东省滨州市中医医院,256600

出　　处：《实用癌症杂志》2019年第2期249-253,共5页The Practical Journal of Cancer

摘　　要：目的探究调胃、强肾扶正液联合吉非替尼分子靶向治疗非小细胞肺癌临床效果及安全性。方法选取60例非小细胞肺癌患者作为研究对象,采取随机数字表法将其分为研究组与对照组,对照组患者(30例)予以吉非替尼分子靶向治疗,研究组患者(30例)在对照组治疗基础上联合调胃、强肾扶正液治疗,对比两组疗效、治疗前后中医症状积分、药物不良副反应、治疗前后患者血清血管内皮生长因子(VEGF)水平及T细胞亚群、治疗后各组生存质量量表(EORTCQLQ-C30)评分情况、随访2年生存时间。结果研究组治疗总有效率为93. 33%,高于对照组73. 33%,P <0. 05;治疗后研究组患者中医症状积分优于对照组,药物不良反应发生率低于对照组,P <0. 05;治疗前各组外周血VEGF水平及CD3+、CD4+、CD4+/CD8+均无差异,P> 0. 05,治疗后研究组患者各项水平均优于对照组,P <0. 05;研究组患者EORTCQLQ-C30评分优于对照组,2年生存时间长于对照组,P <0. 05,差异具有统计学意义。结论调胃、强肾扶正液联合吉非替尼分子靶向治疗非小细胞肺癌临床效果良好,患者症状改善,毒副反应降低,安全可行,且患者免疫能力提升,生存质量改善,2年生存时间延长,具有较高临床推广及应用价值。Objective To investigate the clinical efficacy and safety of non-small-cell lung cancer in the treatment of non-small-cell lung cancer.Methods Select our hospital from January 2014 to January 2016,60 patients with non-small-cell lung cancer(NSCLC)as the research object,take a random number table method,it can be divided into research group and control group,control group(30 cases)in patients with the treatment to the molecular targeted therapy,treatment group patients in the control group(30 cases)based on the joint strong stomach and kidney righting liquid treatment,compared two groups of curative effect and TCM symptom score before and after the treatment,patients with drug adverse reaction,before and after treatment serum vascular endothelial growth factor(VEGF)level and T cell subgroup,groups after treatment quality of life scale(EORTCQLQ-C30)score,followed up for 2 years survival time.Results The total effectiveness of the team was 93.33%,above the control group 73.33%,P<0.05;In the post-treatment group,the treatment of traditional Chinese medicine was better than the control group,and the subrate of the drug was lower than the control group,P<0.05.The levels of the peripheral blood VEGF and CD3+,CD4+,CD4+/CD8+were no different in the preceding groups,with P >0.05,and the group were better than the control group,P<0.05.The study group's patients eortcqlq-c30 scored better than the control group,with a 2-year survival rate of longer than the control group,P<0.05,and the difference was statistically significant.Conclusion Strong stomach and kidney fluid of righting the treatment combined molecular targeted therapy in non-small cell lung cancer clinical effect is good,the symptoms improved,side reaction is reduced,safe and feasible,and the patients with immune ability to ascend,quality of life improved,prolong survival time,2 years has high clinical popularization and application value.

关 键 词：非小细胞肺癌 吉非替尼 分子靶向治疗 调胃、强肾扶正液 

分 类 号：R734.2[医药卫生—肿瘤]